Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
492 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape. Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 49, 18, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 4 molecules, respectively.Bile Duct Cancer (Cholangiocarcinoma). Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology). - The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Bile Duct Cancer (Cholangiocarcinoma) Overview 7 Therapeutics Development 8 Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 10 Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 14 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 15 Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 18 Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 23 Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 24 Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 87 Drug Profiles 101 Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 464 Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 467 Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 468 Appendix 481
List of Tables
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2016 18 Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H2 2016 19 Number of Products under Development by Companies, H2 2016 20 Number of Products under Development by Companies, H2 2016 (Contd..1) 21 Number of Products under Development by Companies, H2 2016 (Contd..2) 22 Number of Products under Development by Companies, H2 2016 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2016 24 Comparative Analysis by Late Stage Development, H2 2016 25 Comparative Analysis by Clinical Stage Development, H2 2016 26 Comparative Analysis by Early Stage Development, H2 2016 27 Products under Development by Companies, H2 2016 28 Products under Development by Companies, H2 2016 (Contd..1) 29 Products under Development by Companies, H2 2016 (Contd..2) 30 Products under Development by Companies, H2 2016 (Contd..3) 31 Products under Development by Companies, H2 2016 (Contd..4) 32 Products under Investigation by Universities/Institutes, H2 2016 33 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H2 2016 34 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 35 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals Inc, H2 2016 36 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals Inc, H2 2016 37 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule Inc, H2 2016 38 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc, H2 2016 39 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 40 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 41 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H2 2016 42 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H2 2016 43 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by BeiGene Ltd, H2 2016 44 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Blueprint Medicines Corp, H2 2016 45 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 46 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical Inc, H2 2016 47 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H2 2016 48 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corp, H2 2016 49 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H2 2016 50 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellceutix Corp, H2 2016 51 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellular Biomedicine Group Inc, H2 2016 52 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Concordia International Corp, H2 2016 53 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 54 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 55 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems Inc, H2 2016 56 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eisai Co Ltd, H2 2016 57 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H2 2016 58 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis Inc, H2 2016 59 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 60 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by H3 Biomedicine Inc, H2 2016 61 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Halozyme Therapeutics Inc, H2 2016 62 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Hutchison MediPharma Ltd, H2 2016 63 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Incyte Corp, H2 2016 64 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Innopharmax Inc, H2 2016 65 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by INSYS Therapeutics Inc, H2 2016 66 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Johnson & Johnson, H2 2016 67 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co Ltd, H2 2016 68 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Loxo Oncology, Inc., H2 2016 69 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co Ltd, H2 2016 70 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by MedImmune LLC, H2 2016 71 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co Inc, H2 2016 72 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NanoCarrier Co Ltd, H2 2016 73 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NormOxys Inc, H2 2016 74 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H2 2016 75 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Ltd, H2 2016 76 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Oasmia Pharmaceutical AB, H2 2016 77 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science Inc, H2 2016 78 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 79 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 80 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech Holding ASA, H2 2016 81 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc, H2 2016 82 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pharma Mar SA, H2 2016 83 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H2 2016 84 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Puma Biotechnology Inc, H2 2016 85 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by RedHill Biopharma Ltd, H2 2016 86 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H2 2016 87 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences Inc, H2 2016 88 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016 89 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 90 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by SynCore Biotechnology Co Ltd, H2 2016 91 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by SyntheX Inc, H2 2016 92 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Taiwan Liposome Company Ltd, H2 2016 93 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by tella Inc, H2 2016 94 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Threshold Pharmaceuticals Inc, H2 2016 95 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics Inc, H2 2016 96 Assessment by Monotherapy Products, H2 2016 97 Assessment by Combination Products, H2 2016 98 Number of Products by Stage and Target, H2 2016 100 Number of Products by Stage and Mechanism of Action, H2 2016 104 Number of Products by Stage and Route of Administration, H2 2016 108 Number of Products by Stage and Molecule Type, H2 2016 110 Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H2 2016 474 Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..1), H2 2016 475 Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..2), H2 2016 476 Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H2 2016 477
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
